Shares of Shield Therapeutics plc (LON:STX – Get Free Report) traded down 11.5% during trading on Tuesday . The company traded as low as GBX 5.19 and last traded at GBX 5.40. 11,462,072 shares were traded during mid-day trading, an increase of 382% from the average session volume of 2,379,675 shares. The stock had previously closed at GBX 6.10.
Shield Therapeutics Stock Performance
The firm has a market capitalization of £59.25 million, a price-to-earnings ratio of -2.77 and a beta of 1.72. The company has a current ratio of 0.75, a quick ratio of 2.16 and a debt-to-equity ratio of -146.28. The stock’s 50-day moving average is GBX 5.36 and its 200-day moving average is GBX 7.01.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- Why China’s Memory Chip Breakthrough Won’t Crash the Market
- Enova’s Earnings Surge Meets a Valuation Test
- SLB’s Kelvion Deal Could Change How Investors Value the Oilfield Giant
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
